Abstract: Methods of detecting the level of inositol trisphosphate receptor (IP3R) free calcium (Ca2+) signaling activity in the cultured cells induced by an agonist of IP3R Ca2+ signaling are described herein. The detection of IP3R Ca2+ signaling allows for diagnosing the risk of a patient or subject for developing an Autism Spectrum Disorder (ASD). Additionally, methods described herein could be used for identifying potential therapeutic anti-ASD agents. The methods for treatment and monitoring of the disease are also outlined.

Abstract: The present invention features methods of detecting the level of inositol trisphosphate receptor (IP3R) free calcium (Ca2+) signaling activity in the cultured cells induced by an agonist of IP3R Ca2+ signaling. The detection of IP3R Ca2+ signaling allows for diagnosing the risk of a patient or subject for developing an Autism Spectrum Disorder (ASD). Additionally, methods described herein could be used for identifying potential therapeutic anti-ASD agents. The methods for treatment and monitoring of the disease are also outlined.

Abstract: The present invention features methods that allow for diagnosing a risk for a patient or subject developing an Autism Spectrum Disorder, for identifying potentially therapeutic anti-ASD agents, and methods for treatment monitoring as specified in the independent claims.

Abstract: The present invention features methods that allow for diagnosing a risk for a patient or subject developing an Autism Spectrum Disorder, for identifying potentially therapeutic anti-ASD agents, and methods for treatment monitoring as specified in the independent claims.

Abstract: Disclosed herein are biomarkers for determining susceptibility to Autism Spectrum Disorder (ASD). Susceptibility to ASD is determined by detecting IP3R Ca2+ signaling activity level in cells, wherein a decrease in IP3R Ca2+ activity is indicative of ASD susceptibility. Also disclosed herein are methods of screening a therapeutic agent for ASD. A candidate drug is determined to be a therapeutic agent for treatment of ASD if the IP3R Ca2+ signaling activity is higher in the presence of the candidate drug than in its absence. Further disclosed herein are methods for prognosis, diagnosis, or treatment for an ASD, comprising determining IP3R Ca2+ signaling activity level in a said biological sample; and comparing it to a reference value from a control subject, where a lower activity level than the reference value in the sample is indicative of the presence of an autism spectrum disorder.